ArticleTransplant international : official journal of the European Society for Organ Transplantation2023
Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Molecular Diagnosis of Early Equivocal Alloimmune Injury After Imlifidase Desensitization in a Kidney Transplant Recipient.Transplantation direct · 2026Article
- Clinical implications of imlifidase interference in antibody screening and transfusion management.Transfusion · 2026Article
- Article
- Article
- Sensitization and Deceased-Donor Kidney Transplant Access in France.Kidney international reports · 2026Article
- Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report.Frontiers in immunology · 2026Article
- Highly sensitized kidney transplant candidates: integrating acceptable mismatch, desensitization, imlifidase, and emerging immune-cell targeting strategies.Frontiers in immunology · 2026Review
- Improved access to kidney transplantation with favorable graft survival in highly sensitized candidates under the French acceptable mismatch program.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Reshaping the landscape of HLA desensitization through immune engineering.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Desensitization With Imlifidase: Overcoming Immunological Barriers in Kidney Transplantation.Kidney medicine · 2025Article
- Escherichia coli in the production of biopharmaceuticals.Biotechnology and applied biochemistry · 2025Review
- The future of nephrology in 2050.Future healthcare journal · 2025Article
- Life beyond antibodies: quality of life after desensitization in kidney transplantation.Clinical kidney journal · 2025Article
- Anti-Human Leukocyte Antigen Antibody Detection from Terasaki's Humoral Theory to Delisting Strategies in 2024.International journal of molecular sciences · 2025Review
- Optimizing HLA desensitization: serum dilution strategies and platform-specific MFI thresholds for antibody-mediated rejection risk in kidney transplantation.Frontiers in immunology · 2025Article
- Imlifidase in Highly Sensitized Kidney Transplant Recipients With a Positive Crossmatch Against a Deceased Donor.Kidney international reports · 2024Article
- Imlifidase in kidney transplantation.Clinical kidney journal · 2024Article
- Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Impact of imlifidase treatment on immunoglobulins in an HLA-hypersensitized lupus nephritis patient with anti-SSA/SSB antibodies after kidney transplantation: A case report.Journal of translational autoimmunity · 2023Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imlifidase recently received early access authorization for highly sensitized adult kidney transplant candidates with a positive crossmatch against an ABO-compatible deceased donor. These French consensus guidelines have been generated by an expert working group, in order to homogenize patient selection, associated treatments and follow-up. This initiative is part of an international effort to analyze properly the benefits and tolerance of this new costly treatment in real-life. Eligible patients must meet the following screening criteria: cPRA ≥ 98%, ≤ 65-year of age, ≥ 3 years on the waiting list, and a low risk of biopsy-related complications. The final decision to use Imlifidase will be based on the two following criteria. First, the results of a virtual crossmatch on recent serum, which shall show a MFI for the immunodominant donor-specific antibodies (DSA) > 6,000 but the value of which does not exceed 5,000 after 1:10 dilution. Second, the post-Imlifidase complement-dependent cytotoxicity crossmatch must be negative. Patients treated with Imlifidase will receive an immunosuppressive regimen based on steroids, rATG, high dose IVIg, rituximab, tacrolimus and mycophenolic acid. Frequent post-transplant testing for DSA and systematic surveillance kidney biopsies are highly recommended to monitor post-transplant DSA rebound and subclinical rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.